keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrine tumour

keyword
https://www.readbyqxmd.com/read/28323985/utility-of-fdg-pet-imaging-for-risk-stratification-of-pancreatic-neuroendocrine-tumours-in-men-1
#1
E R Kornaczewski Jackson, O P Pointon, R Bohmer, J R Burgess
Context: Patients with Multiple Endocrine Neoplasia Type 1 (MEN 1) are at high risk of malignant pancreatic Neuroendocrine Tumours (pNETs). Structural imaging is typically used to screen for pNETs, but is suboptimal for stratifying malignant potential. Objective: To determine the utility of Fluorodeoxyglucose (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting the malignant potential of pNETs in MEN 1. Design: Retrospective observational study...
March 7, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28295664/small-pancreatic-insulinoma-successful-endoscopic-ultrasound-guided-radiofrequency-ablation-in-a-single-session-using-a-22g-fine-needle
#2
Francesc Bas-Cutrina, Domingo Bargalló, Joan B Gornals
A 63-year-old woman, morbidly obese, with clinical symptoms of periodic hypoglycemic episodes, was diagnosed with an insulinoma in pancreatic body that had not been detected by previous computed tomography and magnetic resonance. This neuroendocrine tumour was identified by EUS as a hypoechoic lesion with some iso-hyperechoic tracts, measuring 9 x 10 mm, and 4-5 mm from splenic vessels (Figure 1a). This article is protected by copyright. All rights reserved.
March 14, 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/28292641/evaluating-lanreotide-as-maintenance-therapy-after-first-line-treatment-in-patients-with-non-resectable-duodeno-pancreatic-neuroendocrine-tumours
#3
Côme Lepage, Laetitia Dahan, Nadia Bouarioua, Christos Toumpanakis, Jean-Louis Legoux, Karine Le Malicot, Rosine Guimbaud, Denis Smith, David Tougeron, Astrid Lievre, Guillaume Cadiot, Frédéric Di Fiore, Karine Bouhier-Leporrier, Olivia Hentic, Roger Faroux, Marianne Pavel, Ivan Borbath, Juan W Valle, Anja Rinke, Jean-Yves Scoazec, Michel Ducreux, Thomas Walter
INTRODUCTION: Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained. AIM(S): The aim is to stop chemotherapy until progression...
March 11, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28286565/everolimus-in-the-management-of-metastatic-neuroendocrine-tumours
#4
REVIEW
David L Chan, Eva Segelov, Simron Singh
Neuroendocrine tumours are increasing in incidence and cause a variety of symptoms. The mammalian target of rapamycin (mTOR) pathway plays a key role in neuroendocrine tumour (NET) pathogenesis, leading to increased lipid synthesis, protein synthesis and cellular growth. Upregulation of this pathway is noted in both hereditary and sporadic NETs. This understanding has led to investigations of mTOR inhibitors as therapy for metastatic NETs. After promising preclinical findings, everolimus, an mTOR inhibitor, was trialled in the RADIANT-1-4 studies on patients with advanced, well differentiated NETs...
January 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28267533/neuroendocrine-liver-metastases-vascular-patterns-on-triple-phase-mdct-are-indicative-of-primary-tumour-location
#5
Maxime Ronot, Francesco Cuccioli, Marco Dioguardi Burgio, Marie-Pierre Vullierme, Olivia Hentic, Philippe Ruszniewski, Gaspard d'Assignies, Valérie Vilgrain
PURPOSE: To re-evaluate and compare CT features of neuroendocrine liver metastases (NLM) from pancreatic (p) and enteric (e) gastroenteropancreatic (GEP) tumours. MATERIAL AND METHODS: From 2006-2013, all patients with proven GEP-neuroendocrine tumours (NETs) with at least one NLM, no previous treatment were included. On unenhanced, arterial and portal phases, NLMs were characterized as hypo-, iso- or hyperattenuating in consensus by 2 radiologists blinded to clinical data...
April 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28255147/intrapancreatic-accessory-spleen-an-eluding-diagnosis
#6
K H Teoh, S Balraj, S R Navarasi
Intrapancreatic accessory spleen (IPAS) is a benign anomaly of splenic embryology and a rare cause of pancreatic pseudotumour. Here, we report a case of a 70-year-old Malay lady whose IPAS was discovered incidentally during her surveillance computed tomography for her underlying left lower lung fibrosis. Radiologically, the lesion mimicked a neuroendocrine pancreatic tumour and was only diagnosed pathologically as IPAS after surgery. In conclusion, recognising IPAS as a differential for enhancing pancreatic mass allows us to exhaust all non-invasive diagnostic means to diagnose this benign lesion...
February 2017: Medical Journal of Malaysia
https://www.readbyqxmd.com/read/28250896/endoscopy-guided-ablation-of-pancreatic-lesions-technical-possibilities-and-clinical-outlook
#7
REVIEW
Marianna Signoretti, Roberto Valente, Alessandro Repici, Gianfranco Delle Fave, Gabriele Capurso, Silvia Carrara
Endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP)-guided ablation procedures are emerging as a minimally invasive therapeutic alternative to radiological and surgical treatments for locally advanced pancreatic cancer (LAPC), pancreatic neuroendocrine tumours (PNETs), and pancreatic cystic lesions (PCLs). The advantages of treatment under endoscopic control are the real-time imaging guidance and the possibility to reach a deep target like the pancreas. Currently, radiofrequency probes specifically designed for ERCP or EUS ablation are available as well as hybrid cryotherm probe combining radiofrequency with cryotechnology...
February 16, 2017: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28250297/multimodal-treatment-of-vasoactive-intestinal-polypeptide-producing-pancreatic-neuroendocrine-tumors-with-liver-metastases
#8
Mari Iwasaki, Kouhei Tsuchida, Hidehito Jinnai, Toshinori Komatsubara, Takahiro Arisaka, Misako Tsunemi, Masakazu Nakano, Makoto Iijima, Hideyuki Hiraishi
A 53-year-old man presented with diarrhoea and hypokalaemia and was diagnosed with a neuroendocrine tumour of unknown origin with multiple liver metastases. Somatostatin analogues led to a reduction in the size of the tumours and improvement of his symptoms. However, after several years, the tumours grew in size, and the patient's clinical symptoms recurred. The patient underwent transcatheter arterial embolization (TAE) of the hepatic artery to treat the liver metastases. Immediately after embolization, the symptoms disappeared...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28238592/frequency-of-carcinoid-syndrome-at-neuroendocrine-tumour-diagnosis-a-population-based-study
#9
Daniel M Halperin, Chan Shen, Arvind Dasari, Ying Xu, Yiyi Chu, Shouhao Zhou, Ya-Chen Tina Shih, James C Yao
BACKGROUND: Neuroendocrine tumours (NETs) can secrete bioactive amines into the bloodstream, causing carcinoid syndrome, with symptoms including flushing and diarrhoea. However, carcinoid syndrome frequency in the NET population has never been rigorously assessed, nor has its relationship to presenting clinicopathological characteristics. This analysis assessed the proportion of patients with NETs and carcinoid syndrome in the USA and associated clinical factors. METHODS: We identified patients (≥65 years of age) from the Surveillance, Epidemiology, and End Results-Medicare database, excluding those with pancreatic tumours or small-cell or large-cell lung cancer, as well as those without complete data...
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28237989/enets-consensus-guidelines-for-standard-of-care-in-neuroendocrine-tumours-surgery-for-small-intestinal-and-pancreatic-neuroendocrine-tumours
#10
Stefano Partelli, Detlef K Bartsch, Jaume Capdevila, Jie Chen, Ulrich Knigge, Bruno Niederle, Els J M Nieveen van Dijkum, Ulrich-Frank Pape, Andreas Pascher, John Ramage, Nick Reed, Philippe Ruszniewski, Jean-Yves Scoazec, Christos Toumpanakis, Reza Kianmanesh, Massimo Falconi
No abstract text is available yet for this article.
February 25, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28203372/diagnostic-challenges-and-management-of-a-patient-with-acromegaly-due-to-ectopic-growth-hormone-releasing-hormone-secretion-from-a-bronchial-carcinoid-tumour
#11
Nikolaos Kyriakakis, Jacqueline Trouillas, Mary N Dang, Julie Lynch, Paul Belchetz, Márta Korbonits, Robert D Murray
A male patient presented at the age of 30 with classic clinical features of acromegaly and was found to have elevated growth hormone levels, not suppressing during an oral glucose tolerance test. His acromegaly was originally considered to be of pituitary origin, based on a CT scan, which was interpreted as showing a pituitary macroadenoma. Despite two trans-sphenoidal surgeries, cranial radiotherapy and periods of treatment with bromocriptine and octreotide, his acromegaly remained active clinically and biochemically...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28199314/whole-genome-landscape-of-pancreatic-neuroendocrine-tumours
#12
Aldo Scarpa, David K Chang, Katia Nones, Vincenzo Corbo, Ann-Marie Patch, Peter Bailey, Rita T Lawlor, Amber L Johns, David K Miller, Andrea Mafficini, Borislav Rusev, Maria Scardoni, Davide Antonello, Stefano Barbi, Katarzyna O Sikora, Sara Cingarlini, Caterina Vicentini, Skye McKay, Michael C J Quinn, Timothy J C Bruxner, Angelika N Christ, Ivon Harliwong, Senel Idrisoglu, Suzanne McLean, Craig Nourse, Ehsan Nourbakhsh, Peter J Wilson, Matthew J Anderson, J Lynn Fink, Felicity Newell, Nick Waddell, Oliver Holmes, Stephen H Kazakoff, Conrad Leonard, Scott Wood, Qinying Xu, Shivashankar Hiriyur Nagaraj, Eliana Amato, Irene Dalai, Samantha Bersani, Ivana Cataldo, Angelo P Dei Tos, Paola Capelli, Maria Vittoria Davì, Luca Landoni, Anna Malpaga, Marco Miotto, Vicki L J Whitehall, Barbara A Leggett, Janelle L Harris, Jonathan Harris, Marc D Jones, Jeremy Humphris, Lorraine A Chantrill, Venessa Chin, Adnan M Nagrial, Marina Pajic, Christopher J Scarlett, Andreia Pinho, Ilse Rooman, Christopher Toon, Jianmin Wu, Mark Pinese, Mark Cowley, Andrew Barbour, Amanda Mawson, Emily S Humphrey, Emily K Colvin, Angela Chou, Jessica A Lovell, Nigel B Jamieson, Fraser Duthie, Marie-Claude Gingras, William E Fisher, Rebecca A Dagg, Loretta M S Lau, Michael Lee, Hilda A Pickett, Roger R Reddel, Jaswinder S Samra, James G Kench, Neil D Merrett, Krishna Epari, Nam Q Nguyen, Nikolajs Zeps, Massimo Falconi, Michele Simbolo, Giovanni Butturini, George Van Buren, Stefano Partelli, Matteo Fassan, Kum Kum Khanna, Anthony J Gill, David A Wheeler, Richard A Gibbs, Elizabeth A Musgrove, Claudio Bassi, Giampaolo Tortora, Paolo Pederzoli, John V Pearson, Nicola Waddell, Andrew V Biankin, Sean M Grimmond
The diagnosis of pancreatic neuroendocrine tumours (PanNETs) is increasing owing to more sensitive detection methods, and this increase is creating challenges for clinical management. We performed whole-genome sequencing of 102 primary PanNETs and defined the genomic events that characterize their pathogenesis. Here we describe the mutational signatures they harbour, including a deficiency in G:C > T:A base excision repair due to inactivation of MUTYH, which encodes a DNA glycosylase. Clinically sporadic PanNETs contain a larger-than-expected proportion of germline mutations, including previously unreported mutations in the DNA repair genes MUTYH, CHEK2 and BRCA2...
February 15, 2017: Nature
https://www.readbyqxmd.com/read/28197876/enhancing-pancreatic-mass-with-normal-serum-ca19-9-key-mdct-features-to-characterize-pancreatic-neuroendocrine-tumours-from-its-mimics
#13
Liang Zhu, Hua-Dan Xue, Wei Liu, Xuan Wang, Xin Sui, Qin Wang, Daming Zhang, Ping Li, Zheng-Yu Jin
OBJECTIVES: To determine key MDCT features for characterizing pancreatic neuroendocrine tumours (PNET) from their mimics, which manifest as enhancing pancreatic mass with normal serum CA19-9 level. METHODS: This retrospective study had institutional review board approval and informed consent was waived. Preoperative multiphase MDCT of 74 patients with enhancing pancreatic masses and normal serum CA19-9 levels were included. Surgical pathologies were PNET (n = 42), microcystic serous cystadenomas (m-SCN, n = 12) and solid pseudopapillary epithelial neoplasms (SPEN, n = 20)...
February 15, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28179320/detection-of-somatic-mutations-in-gastroenteropancreatic-neuroendocrine-tumors-using-targeted-deep-sequencing
#14
Samuel Backman, Olov Norlén, Barbro Eriksson, Britt Skogseid, Peter Stålberg, Joakim Crona
Mutations affecting the mechanistic target of rapamycin (MTOR) signalling pathway are frequent in human cancer and have been identified in up to 15% of pancreatic neuroendocrine tumours (NETs). Grade A evidence supports the efficacy of MTOR inhibition with everolimus in pancreatic NETs. Although a significant proportion of patients experience disease stabilization, only a minority will show objective tumour responses. It has been proposed that genomic mutations resulting in activation of MTOR signalling could be used to predict sensitivity to everolimus...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28155290/the-diagnosis-of-bilateral-primary-renal-paragangliomas-in-a-cat
#15
Ryan B Friedlein, Alain J Carter, Robert D Last, Sarah Clift
A 9-year-old sterilised female domestic short-hair cat was referred with a history of vomiting and anorexia of 3 months' duration. Biochemistry, full-blood counts, thoracic radiographs, feline pancreatic-specific lipase, abdominal ultrasonography and feline immunodeficiency virus/feline leukaemia virus (FIV/FeLV) SNAP tests had been performed. Mild hypochloraemia and moderate hypokalaemia were evident on initial presentation. Abdominal ultrasonography initially revealed unilateral renal nodules on the left side...
January 24, 2017: Journal of the South African Veterinary Association
https://www.readbyqxmd.com/read/28152531/chemotherapy-in-well-differentiated-pancreatic-neuroendocrine-tumours-with-ki-67-%C3%A2-10-is-there-a-more-effective-antitumor-regimen-a-retrospective-multicentric-study-of-the-french-group-of-endocrine-tumours-gte
#16
Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, Guillaume Cadiot, Sophie Dominguez, Rosine Guimbaud, Patricia Niccoli, Jean-Louis Legoux, Emmanuel Mitry, Vincent Rohmer, Philippe Ruszniewski, Thomas Walter, Michel Ducreux, Anne Couvelard, Jean-Yves Scoazec, Aline Ramond-Roquin, François-Xavier Caroli-Bosc, Olivia Hentic
No abstract text is available yet for this article.
February 3, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28122378/sequential-everolimus-and-sunitinib-treatment-in-pancreatic-metastatic-well-differentiated-neuroendocrine-tumours-resistant-to-prior-treatments
#17
Anna Angelousi, Kimberly Kamp, Maria Kaltsatou, Dermot O'Toole, Gregory Kaltsas, Wouter de Herder
No abstract text is available yet for this article.
January 26, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28111046/validation-and-comparison-between-current-prognostication-systems-for-pancreatic-neuroendocrine-neoplasms-a%C3%A2-single-institution-experience-with-176-patients
#18
Roxanne Teo, Brian K P Goh, David W M Tai, John C Allen, Tony K H Lim, Jacqueline S G Hwang, Damien M Tan, Ser-Yee Lee, Chung-Yip Chan, Peng-Chung Cheow, Pierce K H Chow, London L P J Ooi, Alexander Y F Chung, Simon Ong
BACKGROUND: This article aims to validate and compare the performance of 6 prognostication systems-the World Health Organization 2010 grading criteria, the European Neuroendocrine Tumour Society and the American Joint Committee for Cancer staging systems, the Memorial Sloan Kettering Cancer Center staging and grading systems, as well as the Bilimoria criteria in a cohort of patients with pancreatic neuroendocrine neoplasms at a single institution. METHODS: A retrospective review of 176 patients with histologically proven pancreatic neuroendocrine neoplasm was performed...
January 19, 2017: Surgery
https://www.readbyqxmd.com/read/28062742/emphysematous-cholecystitis-in-a-patient-with-metastatic-pancreatic-neuroendocrine-tumour
#19
M Khan, M Little, G Campbell, H-U Laasch, T Cooksley
No abstract text is available yet for this article.
January 5, 2017: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28027897/relevance-of-dihydropyrimidine-dehydrogenase-and-thymidylate-synthase-in-patients-with-pancreatic-neuroendocrine-neoplasms-treated-with-5-fu-based-chemotherapy
#20
S Krug, M Boch, W Nimphius, T M Gress, P Michl, A Rinke
BACKGROUND: Chemotherapy with 5-FU and Streptozotocin (STZ) is recommended as first-line treatment in patients with metastatic pancreatic neuroendocrine neoplasms (PNEN). However, data about biomarkers involved in the 5-FU metabolism to predict response are still limited. OBJECTIVES: Evaluation of clinicopathological features and potential predictive and prognostic markers of patients with PNEN treated with 5-FU based regimens. PATIENTS AND METHODS: We retrospectively analyzed 41 patients with PNEN who were treated at the University Hospital Marburg between 2000 and 2013...
December 22, 2016: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
keyword
keyword
61812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"